Dietary and pharmacological control of calcium and phosphate metabolism in dialysis patients

Blood Purification

Volumn 27, Issue 4, 2009, Pages 369-386

  Bover, J ^a,b   Andres E ^a   Lloret, M J ^a   Aguilar, A ^a   Ballarin J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b FUNDACIÓ PUIGVERT   (Spain)

Author keywords

Adynamic bone disease; Calcimimetics; Chronic kidney disease; Lanthanum; Paricalcitol; Phosphorus binders; Secondary hyperparathyroidism; Sevelamer; Vascular calcification; Vitamin D

Indexed keywords

ALFACALCIDOL; ALUMINUM HYDROXIDE; CALCIFEDIOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; COLECALCIFEROL; COLESTILAN; ERGOCALCIFEROL; FAMOTIDINE; LANSOPRAZOLE; LANTHANUM CARBONATE; MAGNESIUM; NICERITROL; NICOTINAMIDE; NICOTINIC ACID; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; POLYPEPTIDE; RESIN; SEVELAMER; SEVELAMER CARBONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ALUMINUM OVERLOAD; BLOOD TOXICITY; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CALCIFICATION; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; DIET THERAPY; DRUG FATALITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FAILURE; METABOLIC DISORDER; NEUROTOXICITY; NONHUMAN; OSTEOPOROSIS; PARATHYROID CARCINOMA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRACTICE GUIDELINE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY;

BONE DISEASES; CALCIUM; HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHATES;

EID: 62349141393     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209250     Document Type: Review

References (196)

1. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. Fernández-Llama P, Bover J: Is albuminuria a marker of arterial remodeling? J Hypertens 2008; 26: 633-635.
4. Zoccali C: Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006; 70: 26-33.
5. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
6. Bover J, Canal C, Marco H, Fernandez-Llama P, Bosch RJ, Ballarín J: Diagnostic procedures and rationale for specific therapies in chronic kidney disease-mineral and bone disorder. Contrib Nephrol 2008; 161: 222-233.
7. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
8. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
9. London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Métivier F: Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620.
10. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca ! PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138.
11. Danese MD, Belozeroff V, Smirnakis K, Rothman KJ: Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1423-1429.
12. Tentori F, Hunt WC, Rohrscheib M, Zhu M, Stidley CA, Servilla K, Miskulin D, Meyer KB, Bedrick EJ, Johnson HK, Zager PG: Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? J Am Soc Nephrol 2007; 18: 2377-2384.
13. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
14. Llach F, Bover J: Renal osteodystrophies; in Brenner BM (ed): The Kidney. Philadelphia, Saunders, 2000, pp 2103-2186.
15. Bover J, Jara A, Trinidad P, Rodriguez M, Martín-Malo A, Felsenfeld AJ: The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia. Kidney Int 1994; 46: 310-317.
16. Bover J, Rodríguez M, Trinidad P, Jara A, Martínez ME, Machado L, Llach F, Felsenfeld AJ: Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. Kidney Int 1994; 45: 953-961.
17. Slatopolsky E, Bricker NS: The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 1973; 4: 141-145.
18. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(suppl 3):S1-S201.
19. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
20. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 65: 1815-1824.
21. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 42: 1478-1483.
22. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE: The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255-1261.
23. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
24. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187.
25. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357.
26. Moe SM, Chertow GM: The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 2006; 1: 697-703.
27. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779.
28. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482.
29. Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O'Dea R, Murray DC, Barre PE: Hypocalcemia, morbidity, and mortality in endstage renal disease. Am J Nephrol 1996; 16: 386-393.
30. Almadén Y, Canalejo A, Hernández A, Ballesteros E, García-Navarro S, Torres A, Rodríguez M: Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 1996; 11: 970-976.
31. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 293-295.
32. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G, Cholesterol and Recurrent Events Trial Investigators: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
33. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R: Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74: 148-157.
34. Achinger SG, Ayus JC: Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? J Am Soc Nephrol 2006; 17(12 suppl 3):S255-S261.
35. Uribarri J: Dietary approach to hyperphosphatemia in renal failure patients. http:// cin2007.uninet.edu/en/trabajos/show/11. html; last accessed October 24th, 2008.
36. Takeda E, Yamamoto H, Nishida Y, Sato T, Sawada N, Taketani Y: Phosphate restriction in diet therapy. Contrib Nephrol 2007; 155: 113-124.
37. Uribarri J, Calvo MS: Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial 2003; 16: 186-188.
38. Murphy-Gutekunst L: Hidden phosphorus: where do we go from here? J Ren Nutr 2007; 4:e31-e36.
39. Uribarri J: Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial 2007; 20: 295-301.
40. Sullivan CM, Leon JB, Sehgal AR: Phosphorus-containing food additives and the accuracy of nutrient databases: implications for renal patients. J Ren Nutr 2007; 17: 350-354.
41. Kuhlmann MK, Hoechst S, Landthaler I: Patient empowerment in the management of hyperphosphatemia. Int J Artif Organs 2007; 30: 1008-1013.
42. Sehgal AR, Sullivan C, Leon JB, Bialostosky K: Public health approach to addressing hyperphosphatemia among dialysis patients. J Ren Nutr 2008; 18: 256-261.
43. Bover J, Ortiz-Herbener F, Ballarín J, Andrés E, Barceló P: New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments. Nefrologia 2005; 25(suppl 2):100-108.
44. Felsenfeld AJ, Gutman RA, Llach F, Harrelson JM: Osteomalacia in chronic renal failure: a syndrome previously reported only with maintenance dialysis. Am J Nephrol 1982; 2: 147-154.
45. González EA, Martin KJ: Aluminum and renal osteodystrophy. A diminishing clinical problem. Trends Endocrinol Metab 1992; 3: 371-375.
46. Arenas MD, Malek T, Gil MT, Moledous A, Núñez C, Alvarez-Ude F: Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era. Nefrologia 2008; 28: 168-173.
47. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951.
48. London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC: Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008; 19: 1827-1835.
49. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
50. Sheikh MS, Maquire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS: Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989; 83: 66-73.
51. Hardy P, Sechet A, Hottelart C, Oprisiu R, Abighanem O, Said S, Rasombololona M, Brazier M, Moriniere P, Achard JM, Pruna A, Fournier A: Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. Artif Organs 1998; 22: 569-573.
52. Matsunaga C, Izumi S, Furukubo T, Satoh M, Yamakawa T, Uchida T, Kadowaki D, Hirata S: Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy. Clin Nephrol 2007; 68: 93-98.
53. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E: Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in longterm experimental uremia. Kidney Int 2003; 64: 1653-1661.
54. Phan O, Ivanovski O, Nikolov IG, Joki N, Maizel J, Louvet L, Chasseraud M, Nguyen-Khoa T, Lacour B, Drüeke TB, Massy ZA: Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failure. Nephrol Dial Transplant 2008; 23: 82-90.
55. Bolland MJ, Barber PA, Doughty RN, Mason B, Horne A, Ames R, Gamble GD, Grey A, Reid IR: Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008; 336: 262-266.
56. Floege J: Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them? Nephrol Dial Transplant 2008; 23: 3050-3052.
57. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M; CARE- 2 Investigators: A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965.
58. St Peter WL, Liu J, Weinhandl E, Fan Q: A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008; 51: 445-454.
59. Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B, Alberta Kidney Disease Network: Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22: 2856-2866.
60. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fisher D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137.
61. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
62. Bushinsky DA: Phosphate and its binders. Nephrol Self Assess Program 2008; 7: 295-298.
63. Nikolov IG, Joki N, Maizel J, Lacour B, Drüeke TB, Massy ZA: Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int Suppl 2006; 105:S16-S23.
64. Kraut JA, Kurtz I: Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis 2005; 45: 978-993.
65. Mendoza FJ, Lopez I, Montes de Oca A, Perez J, Rodriguez M, Aguilera-Tejero E: Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney Int 2008; 73: 407-414.
66. Jara A, Felsenfeld AJ, Bover J, Kleeman CR: Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease. Kidney Int 2000; 58: 1023-1032.
67. Delmez J, Block G, Robertson J, Chasan-Taber S, Blair A, Dillon M, Bleyer AJ: A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007; 68: 386-391.
68. Finn WF, SPD 405-307 Lanthanum Study Group: Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006; 65: 191-202.
69. Cozzolino M, Brancaccio D: Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate. Int J Artif Organs 2007; 30: 293-300.
70. Altmann P, Barnett ME, Finn WF, SPD405-307 Lanthanum Carbonate Study Group: Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 2007; 71: 252-259.
71. Persy VP, Behets GJ, Bervoets AR, de Bre ME, D'Haese PC: Lanthanum: a safe phosphate binder. Semin Dial 2006; 19: 195-199.
72. Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M, for the Fosrenol Overview Research Evaluation Study for Early Experience (FORESEE) Study Group: Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol 2008; 3: 1437-1445.
73. Hutchison AJ, Laville M, SPD-405-313 Lanthanum Study Group: Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 2008; 23: 3677-3684.
74. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008.
75. de Freitas D, Donne RL, Hutchison AJ: Lanthanum carbonate-a first line phosphate binder? Semin Dial 2007; 20: 325-328.
76. Date T, Shigematsu T, Kawashita Y, Satake N, Morita K: Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol Dial Transplant 2003; 18(suppl 3):90-93.
77. Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, Kono T, Uchino J, Masaki K, Date T, Shigematsu T, Research Group for Future Hemodialysis: Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Ther Apher Dial 2008; 12: 126-132.
78. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN: Extended release nicotinic acid-a novel oral agent for phosphate control. Int Urol Nephrol 2006; 38: 171-174.
79. Restrepo Valencia CA, Cruz J: Safety and effectiveness f nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia. Nefrologia 2008; 28: 61-66.
80. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, Ebihara I, Koide H: Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004; 65: 1099-1104.
81. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW: A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1131-1138.
82. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, Mc-Cary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
83. Levin NW, Gotch FA, Kuhlmann MK: Factors for increased morbidity and mortality in uremia: hyperphosphatemia. Semin Nephrol 2004; 24: 396-400.
84. Benaroia M, Pierratos A, Nesrallah GE: A primer for the prescription of short-daily and nocturnal hemodialysis. Hemodial Int 2008; 12: 23-29.
85. Maduell F, Navarro V, Torregrosa E, Rius A, Dicenta F, Cruz MC, Ferrero JA: Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int 2003; 64: 305-313.
86. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P: Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006; 70: 345-350.
87. de la Piedra C, Fernández E, González Casaus ML, González-Parra E: Different biological functions in PTH molecules. What are we measuring? Nefrologia 2008; 28: 123-128.
88. Torres A, Lorenzo V, Hernández D, Rodríguez JC, Concepción MT, Rodríguez AP, Hernández A, de Bonis E, Darias E, González- Posada, et al: Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442.
89. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y: Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995; 26: 836-844.
90. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Dusso A: A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 568: 753-761.
91. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, et al: Incidence and risks factors for hip and other bone fractures among hemodialysis patients in the DOPPS. Kidney Int 2006; 70: 1358-1366.
92. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM: PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149-156.
93. Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E: Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007; 22: 1171-1176.
94. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
95. Górriz JL, Bover J, Caravaca F, Barril G, Molinero LM, de Francisco AM, Oserce Study group. 'OSERCE' Multicenter Spanish Study: vitamin D levels in CKD stages 3-5 predialysis (abstract). Nephrol Dial Transplant 2007; 22(suppl 6):vi173.
96. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: Daily oral 25- hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 2008; 23: 3670-3676.
97. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
98. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511.
99. Melamed ML, Michos ED, Post W, Astor B: 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629-1637.
100. Hamada Y, Fukagawa M: The pleiotropic effects of vitamin D on kidney disease. Clin Calcium 2007; 17: 712-717.
101. Matias PJ, Ferreira C, Jorge C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A: 25-Hydroxyvitamin D 3 , arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 611-618.
102. Tokmak F, Quack I, Schieren G, Sellin L, Rattensperger D, Holland-Letz T, Weiner SM, Rump LC: High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 4016-4020.
103. Blair D, Byham-Gray L, Lewis E, McCaffrey S: Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D 2 ) in stage 5 chronic kidney disease patients. J Ren Nutr 2008; 18: 375-382.
104. Hernandez JD, Wesseling K, Boechat MI, Gales B, Salusky IB: Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol. Nat Clin Pract Nephrol 2007; 3: 227-232.
105. Gallieni M, Kamimura S, Ahmed A, Bravo E, Delmez J, Slatopolsky E, Dusso A: Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 1995; 268:F746-F753.
106. Al-Badr W, Martin KJ: Vitamin D and kidney disease. Clin J Am Soc Nephrol 2008; 3: 1555-1560.
107. Carrillo-López N, Alvarez-Hernández D, González- Suárez I, Román-García P, Valdivielso JM, Fernández-Martín JL, Cannata-Andía JB: Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol. Nephrol Dial Transplant 2008; 23: 3479-3484.
108. Rodriguez ME, Almaden Y, Cañadillas S, Canalejo A, Siendones E, Lopez I, Aguilera- Tejero E, Martin D, Rodriguez M: The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 2007; 292: F1390-F1395.
109. Garfia B, Cañadillas S, Canalejo A, Luque F, Siendones E, Quesada M, Almadén Y, Aguilera-Tejero E, Rodríguez M: Regulation of parathyroid vitamin D receptor expression by extracellular calcium. J Am Soc Nephrol 2002; 13: 2945-2952.
110. Bover J, Ballarín J, Andrés E, Ortiz-Herbener F, Barceló P: New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium- mimetics. Nefrologia 2005; 25(suppl2):109-116.
111. Slatopolsky E, Cozzolino M, Finch JL: Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int 2002; 62: 1277-1284.
112. Vervloet MG, Twisk JW: Mortality reduction by vitamin D receptor activation in end-stage renal disease: a commentary on the robustness of current data. Nephrol Dial Transplant 2008, Epub ahead of print.
113. Marco MP, Craver L, Betriu A, Fibla J, Fernández E: Influence of vitamin D receptor gene polymorphisms on mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38: 965-974.
114. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D 3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184.
115. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
116. Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andía JB: Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078.
117. Andress DL: Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43.
118. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG; Medical Directors of Dialysis Clinic Inc: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.
119. Balint E, Marshall CF, Sprague SM: Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. Am J Kidney Dis 2000; 36: 789-796.
120. Monier-Faugere MC, Mawad H, Malluche HH: Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal- parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 1255-1260.
121. Andress DL: Adynamic bone in patients with chronic kidney disease. Kidney Int 2008; 73: 1345-1354.
122. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM: Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007; 104: 16810-16815.
123. Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM: Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-866.
124. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M: The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307.
125. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E: Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715.
126. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
127. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM: Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-276.
128. Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA,Hamm LL, Sprague SM: Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 2008; 28: 97-106.
129. Huang C, Miller RT: The calcium-sensing receptor and its interacting proteins. J Cell Mol Med 2007; 11: 923-934.
130. Levi R, Ben-Dov IZ, Lavi-Moshayoff V, Dinur M, Martin D, Naveh-Many T, Silver J: Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. J Am Soc Nephrol 2006; 17: 107-112.
131. Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, Egea JJ, Millán I, Amoedo ML, Muray S, Carretón MA: Application of NKF-K/ DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 2006; 21: 1663-1668.
132. Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F: The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36-45.
133. Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C, Devesa R, Carretón MA, Soriano A: Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007; 22: 1639-1644.
134. Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA, TARGET Investigators: Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008; 23: 2311-2318.
135. Schaefer RM, Bover J, Dellanna F, Sanz D, Asensio C, Sánchez González MC, Gross P, Zani V, Carter D, Jehle PM: Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study. Clin Nephrol 2008; 70: 126-134.
136. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800.
137. Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, Reed J, CONTROL Investigators: Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium ! phosphate. Clin J Am Soc Nephrol 2006; 1: 305-312.
138. Torregrosa JV, Cannata Andia J, Bover J, Caravaca F, Lorenzo V, Martín de Francisco AL, Martín-Malo A, Martínez I, González Parra E, Fernández Giráldez E, Rodríguez Portillo M, Sociedad Española de Nefrologia: SEN Guidelines. Recommendations of the Spanish Society of Nephrology for managing bone - mineral metabolic alterations in chronic renal disease patients (in Spanish). Nefrologia 2008; 28(suppl 1):1-22.
139. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807.
140. D'Amour P, Palardy J, Bahsali G, Mallette LE, DeLéan A, Lepage R: The modulation of circulating parathyroid hormone immunoheterogeneity in man by ionized calcium concentration. J Clin Endocrinol Metab 1992; 74: 525-532.
141. Garside R, Pitt M, Anderson R, Mealing S, D'Souza R, Stein K: The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 2007; 22: 1428-1436.
142. Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, et al: Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE Study Results. Clin J Am Soc Neprol 2008; 3: 1718-1725.
143. Bover J, Canal C, Pérez S, Bosch R, Ballarín J: Slowing the progression of vascular calcification in chronic kidney disease patients. Eur Ren Dis 2007; 1: 18-23.
144. Amann K: Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1599-1605.
145. Wang L, Jerosch-Herold M, Jacobs DR Jr, Shahar E, Detrano R, Folsom AR, MESA Study Investigators: Coronary artery calcification and myocardial perfusion in asymptomatic adults: the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2006; 48: 1018-1026.
146. Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhães AO, Custódio MR, Batista DG, Jorgetti V, Moysés RM: Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71: 1262-1270.
147. Inaba M, Okuno S, Imanishi Y, Yamada S, Shioi A, Yamakawa T, Ishimura E, Nishizawa Y: Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006; 17: 1506-1513.
148. Floege J: Calcium containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them? Nephrol Dial Transplant 2008; 23: 3050-3052.
149. Chen NX, Moe SM: Uremic vascular calcification. J Investig Med 2006; 54: 380-384.
150. Yamada K, Fujimoto S, Nishiura R, Komatsu H, Tatsumoto M, Sato Y, Hara S, Hisanaga S, Ochiai H, Nakao H, Eto T: Risk factors of the progression of abdominal aortic calcification in patients on chronic haemodialysis. Nephrol Dial Transplant 2007; 22: 2032-2037.
151. Wang AY, Woo J, Wang M, Sea MM, Ip R, Li PK, Lui SF, Sanderson JE: Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2001; 12: 1927-1936.
152. Danziger J: Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol 2008; 3: 1504-1510.
153. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861.
154. Moe SM, Chen NX: Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19: 213-216.
155. Proudfoot D, Shanahan CM: Molecular mechanisms mediating vascular calcification: role of matrix Gla protein. Nephrology (Carlton) 2006; 11: 455-461.
156. Shroff RC, Shanahan CM: The vascular biology of calcification. Semin Dial 2007; 20: 103-109.
157. Kizu A, Jono S: Mechanism of vascular calcification. Clin Calcium 2004; 14: 92-96.
158. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein alpha 2-Heremans-Schmid glycoprotein/ fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366.
159. Bas A, Lopez I, Perez J, Rodriguez M, Aguilera- Tejero E: Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res 2006; 21: 484-490.
160. Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, Kabaya T, Akiba T, Nitta K: Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract 2008; 108:c278-c283.
161. Schmermund A, Achenbach S, Budde T, Buziashvili Y, Förster A, Friedrich G, Henein M, Kerkhoff G, Knollmann F, Kukharchuk V, Lahiri A, Leischik R, Moshage W, Schartl M, Siffert W, Steinhagen-Thiessen E, Sinitsyn V, Vogt A, Wiedeking B, Erbel R: Effect of intensive versus standard lipidlowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 2006; 113: 427-437.
162. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
163. Zittermann A, Koerfer R: Protective and toxic effects of vitamin D on vascular calcification: clinical implications. Mol Aspects Med 2008; 29: 423-432.
164. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA: Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008; 19: 1509-1519.
165. Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Gonçalves M, Negrao AP: A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1480-1488.
166. Kaupila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW: New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 1997; 132: 245-250.
167. Barraclough KA, Stevens LA, Er L, Rosenbaum D, Brown J, Tiwari P, Levin A: Coronary artery calcification scores in patients with chronic kidney disease prior to dialysis: reliability as a trial outcome measure. Nephrol Dial Transplant 2008; 23: 3199-3205.
168. Vincent M, Brandenburg, Jürgen F: Adynamic bone disease-bone and beyond. Nephrol Dial Transplant plus 2008; 1: 135-147.
169. Andress DL: Adynamic bone in patients with chronic kidney disease. Kidney Int 2008; 73: 1345-1354.
170. Malluche HH, Mawad H, Monier-Faugere MC: The importance of bone health in endstage renal disease: out of the frying pan, into the fire? Nephrol Dial Transplant 2004; 19(suppl 1):i9-i13.
171. Rocha LA, Higa A, Barreto FC, dos Reis LM, Jorgetti V, Draibe SA, Carvalho AB: Variant of adynamic bone disease in hemodialysis patients: fact or fiction? Am J Kidney Dis 2006; 48: 430-436.
172. Andress DL, Howard GA, Birnbaum RS: Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma. Kidney Int 1991; 39: 942-945.
173. Barreto FC, Barreto DV, Moysés RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB: K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777.
174. Parfitt AM: Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 2003; 12: 387-403.
175. Haris A, Sherrard DJ, Hercz G: Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int 2006; 70: 931-937.
176. Spasovski G, Gelev S, Masin-Spasovska J, Selim G, Sikole A, Vanholder R: Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone 2007; 41: 698-703.
177. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; 85:S73-S78.
178. Ferreira A, Frazão JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH, Sevelamer Study Group: Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19: 405-412.
179. Ishii H, Wada M, Furuya Y, Nagano N, Nemeth EF, Fox J: Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000; 26: 175-182.
180. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C: Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396-399.
181. Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J, Osteoporosis Work Group: Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004; 43: 566-571.
182. Stehman-Breen C: Bone mineral density measurements in dialysis patients. Semin Dial 2001; 14: 228-229.
183. Coco M, Rush H: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121.
184. Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC: Progression of aortic alcification is associated with metacarpal bone loss during menopause: a populationbased longitudinal study. Arterioscler Thromb Vasc Biol 2000; 20: 1926-1931.
185. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW: Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int 2001; 68: 271-276.
186. Taal MW, Roe S, Masud T, Green D, Porter C, Cassidy MJ: Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 2003; 63: 1116-1120.
187. Torregrosa JV, Cannata Andia J, Bover J, et al: SEN Guidelines. Recommendations of the Spanish Society of Nephrology for managing one-mineral metabolic alterations in chronic renal disease patients. Nefrologia 2008; 28(suppl 1):1-22.
188. Hashiba H, Aizawa S, Tamura K, Kogo H: Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial 2006; 10: 59-64.
189. Narayan R, Perkins RM, Berbano EP, Yuan CM, Neff RT, Sawyers ES, Yeo FE, Vidal-Trecan GM, Abbott KC: Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007; 49: 801-813.
190. Dussol B, Morand P, Martinat C, Lombard E, Portugal H, Brunet P, Berland Y: Influence of parathyroidectomy on mortality in hemodialysis patients: a prospective observational study. Ren Fail 2007; 29: 579-586.
191. Chan FK, Tiu SC, Choi KL, Choi CH, Kong AP, Shek CC: Increased bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 2003; 88: 3155-3159.
192. Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, Stehman-Breen C: Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66: 2010-2016.
193. Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B: Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 2007; 18: 2401-2407.
194. Kaye M: Parathyroidectomy in end-stage renal disease. J Lab Clin Med 1989; 114: 334-335.
195. Yajima A, Inaba M, Tominaga Y, Ito A: Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int 2008; 74: 775-781.
196. Danziger J: The bone-renal axis in early chronic kidney disease: an emerging paradigm. Nephrol Dial Transplant 2008; 23: 2733-2737.